4-Methylmorpholine → (R)-4-methyl-3-{4-[4-(4-methylbenzoyl)piperidine-1-carbonyl]phenyl}oxazolidin-2-one
反応式
[CH3:1][C@@H:2]1[CH2:6][O:5][C:4](=[O:7])[N:3]1[C:8]1[CH:16]=[CH:15][C:11]([C:12]([OH:14])=O)=[CH:10][CH:9]=1.Cl.[CH3:18][C:19]1[CH:24]=[CH:23][C:22]([C:25]([CH:27]2[CH2:32][CH2:31][NH:30][CH2:29][CH2:28]2)=[O:26])=[CH:21][CH:20]=1.O.[Cl-].COC1N=C(OC)N=C([N+]2(C)CCOCC2)N=1.CN1CCOCC1.[OH-].[Na+]>CO.C(Cl)(Cl)Cl>[CH3:1][C@@H:2]1[CH2:6][O:5][C:4](=[O:7])[N:3]1[C:8]1[CH:9]=[CH:10][C:11]([C:12]([N:30]2[CH2:31][CH2:32][CH:27]([C:25](=[O:26])[C:22]3[CH:21]=[CH:20][C:19]([CH3:18])=[CH:24][CH:23]=3)[CH2:28][CH2:29]2)=[O:14])=[CH:15][CH:16]=1参加物
8
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
To a mixture of (R)-4-(4-methyl-2-oxooxazolidin-3-yl)benzoic acid (633 mg) described in Preparation Example 37, (4-methylphenyl)piperidin-4-ylmethanone hydrochloride (719 mg) and 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride hydrate (DMT-MM) (1.2 g) were added chloroform (3 mL), methanol (3 mL) and N-methylmorpholine (330 μL), and the mixture was stirred at room temperature overnight. To the reaction mixture was added 1N aqueous sodium hydroxide solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, and the solvent was evaporated. The residue was purified by column chromatography (hexane:ethyl acetate) to give the title compound (989 mg).
後処理
- extractionthe mixture was extracted with chloroform
- washThe organic layer was washed with saturated brine
- customthe solvent was evaporated
- customThe residue was purified by column chromatography (hexane:ethyl acetate)
出典と根拠
- ORDレコード
- ord-c0ae82b080cc43199afc6970cc813d07
- 出典データセット
- uspto-grants-2013_01
- 特許番号
- US08354401B2
反応ノート
読み込み中…